News
AMRI Increases Hydroxychloroquine Sulfate API Production in U.S. to Meet Potential COVID-19 Demand
AMRI announced its ongoing commitment to do its part in support of public health needs amidst the COVID-19 pandemic. The company continues to focus on the safety of its employees, assuring supply of critical raw materials, active pharmaceutical ingredients...
News
Applied BioMath, LLC Announces Collaboration with Zymeworks
Applied BioMath, the industry-leader in applying systems pharmacology and mechanistic modeling, simulation, and analysis to de-risk drug research and development, announced the continuation of their collaboration with Zymeworks Inc. Applied BioMath will design and deliver a systems pharmacology model...
News
Vaxart Announces Additional Positive Pre-Clinical Data for its Oral COVID-19 Vaccine Program
Vaxart, Inc., a clinical-stage biotechnology company developing oral recombinant vaccines that are administered by tablet rather than by injection, announced that it has obtained positive pre-clinical results for its COVID-19 vaccine candidates, with several of the vaccine candidates generating...
News
Aridis Pharmaceuticals Enrolls Its First COVID-19 Patient in Ongoing Phase 3 AR-301 Clinical Trial in Ventilator Associated Pneumonia
Aridis Pharmaceuticals, Inc., a biopharmaceutical company focused on the discovery and development of novel anti-infective therapies to treat life-threatening bacterial infections, announced the enrollment of its first COVID-19 patient in the Company's ongoing Phase 3 clinical trial of AR-301,...
News
Massachusetts Hospital to Assess Mallinckrodt’s Nitric Oxide Treatment for COVID-19
Mallinckrodt and Massachusetts General Hospital teamed up to evaluate the potential benefits of inhaled nitric oxide as a treatment for pulmonary complications in patients infected with COVID-19.
The partnership will assess the benefit of INOmax (nitric oxide) gas in mechanically...
Drug Research
Trio pharmaceuticals and ajinomoto bio pharma services enter into a development collaboration for a novel antibody therapeutic
Trio Pharmaceuticals, Inc., a cancer therapeutics company developing novel dual action antibody drugs, and Ajinomoto Bio-Pharma Services, have entered a development collaboration to evaluate AJICAP, a site-specific conjugation technology offered by Aji Bio-Pharma for the development of TRIObody Drug...
News
Gilead’s drug remdesivir gets US FDA’s emergency use authorisation for COVID-19
Gilead was granted EUA by U.S. FDA for the investigational antiviral remdesivir to treat COVID-19. The EUA will facilitate broader use of remdesivir to treat hospitalized patients with severe COVID-19 disease, enabling access to remdesivir at additional hospitals across...
Subscribe
- Never miss a story with notifications
- Gain full access to our premium content
- Browse free from any location or device.
Must read